$NMTR News
Last published 3y ago
- 3y agoNMTR9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel SyndromeACCESS NewswireRALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. , a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the
- 3y agoNMTR9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023ACCESS NewswireRALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. , a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business
- 3y agoNMTR9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for ObesityACCESS NewswireRALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. , a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of
- 3y agoNMTR9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022ACCESS NewswireRALEIGH, NC / ACCESSWIRE / March 28, 2023 / 9 Meters Biopharma, Inc. , a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview
- 3y agoAGRXGNTANMTRPGCorium Pharma Solutions Appoints Mark Sirgo as Chief Executive OfficerBusiness WireCorium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal
- 4y agoNMTR9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel SyndromeACCESS NewswireVurolenatide 50 mg every two weeks (Q2W) dosing arm demonstrated a 30% reduction over six weeks in the primary endpoint of the Phase 2 study, mean reduction in total stool output (TSO), compared with a 32% increase for placebo - for a mean relative redu
- 4y agoNMTR9 Meters Biopharma to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceACCESS NewswireRALEIGH, NC / ACCESSWIRE / September 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Ex
- 4y agoNMTR9 Meters Biopharma to Participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) CongressACCESS NewswireRALEIGH, NC / ACCESSWIRE / September 1, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the company will participate at the
- 4y agoNMTR9 Meters Biopharma to Participate in the Citi 17th Annual BioPharma ConferenceACCESS NewswireRALEIGH, NC / ACCESSWIRE / August 31, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that the Company will participate in Citi's
- 4y agoNMTR9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022ACCESS NewswirePositive preliminary results from Phase 2 VIBRANT study of vurolenatide in short bowel syndrome announced Vurolenatide End-of-Phase 2 meeting with FDA on track for 3Q Cash balance as of June 30, 2022 of $29.5 million; additional $20 million from previ
- 4y agoNMTR9 Meters Biopharma to Exhibit at Digestive Disease Week 2022ACCESS NewswireRALEIGH, NC / ACCESSWIRE / May 19, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced that the company will host an exhibit at Digestive D
- 4y agoNMTR9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Use of Larazotide in Idiopathic Pulmonary FibrosisACCESS NewswireRALEIGH, NC / ACCESSWIRE / May 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced that Matthew Bryant, PharmD, Vice President of Medic
- 4y agoNMTR9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022ACCESS NewswireOn track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in June Cash balance as of March 31, 2022, of $37.2 million is expected to fund ongoing clinical programs and business operations
- 4y agoNMTR9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation SymposiumACCESS NewswireRALEIGH, NC / ACCESSWIRE / May 5, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executiv
- 4y agoNMTR9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac DiseaseACCESS NewswireRALEIGH, NC and SANTA ROSA, CA / ACCESSWIRE / April 20, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, and Celiac.com, a news, information, and
- 4y agoNMTR9 Meters Biopharma Announces Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious Metabolic ConditionsACCESS NewswireRALEIGH, NC / ACCESSWIRE / April 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that the Company has received notice from th
- 4y agoNMTR9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021ACCESS NewswireRALEIGH, NC / ACCESSWIRE / March 23, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, impor
- 4y agoNMTR9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth ConferenceACCESS NewswireRALEIGH, NC / ACCESSWIRE / March 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Execu
- 4y agoNMTR9 Meters Biopharma to Present at the Oppenheimer 32nd Annual Healthcare ConferenceACCESS NewswireRALEIGH, NC / ACCESSWIRE / March 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Execut
- 4y agoNMTR9 Meters Biopharma Announces a Collaboration with NYU Langone Health Investigating NM-102 as a Potential Treatment for an Autoimmune DisorderACCESS NewswireRALEIGH, NC / ACCESSWIRE / March 2, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today a collaboration with NYU Langone Health inves
- 4y agoNMTR9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac DiseaseACCESS NewswireRALEIGH, NC / ACCESSWIRE / February 28, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today an update on its late stage pipeline prod
- 4y agoNMTR9 Meters Biopharma Announces Publication of Data on Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C)ACCESS NewswireRALEIGH, NC / ACCESSWIRE / February 25, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the publication of encouraging data in the jour
- 4y agoNMTR9 Meters Biopharma to Present at the 2022 BIO CEO & Investor ConferenceACCESS NewswireRALEIGH, NC / ACCESSWIRE / February 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today that John Temperato, President & Chief Exec
- 4y agoNMTR9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint InhibitorsACCESS NewswireRALEIGH, NC / ACCESSWIRE / January 24, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that the Company has received notice from
- 4y agoNMTR9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial OfficerACCESS NewswireFormerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experience RALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company
- 4y agoCCJLODENKLANMTR+1Thinking about buying stock in 9 Meters Biopharma, TherapeuticsMD, Cameco Corp, Nikola Corp, or Comstock Mining?PR NewswireNEW YORK, Jan. 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NMTR, TXMD, CCJ, NKLA, and LODE. To
- 4y agoNMTR9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor ConferencesACCESS NewswireRALEIGH, NC / ACCESSWIRE / January 4, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today announc
- 4y agoNMTR9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate CommunicationsACCESS NewswireRALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR),a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company ha
- 4y agoADTXAEVAEFOINMTR+1Thinking about buying stock in Energy Focus, 9 Meters Biopharma, Aditxt, ReTo Eco-Solutions, or Aeva Technologies?PR NewswireNEW YORK, Dec. 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EFOI, NMTR, ADTX, RETO, and AEVA.
- 4y agoNMTR9 Meters Biopharma, Inc. Awards Unrestricted Educational Grant Funding to Carol Rees Parrish, M.S., RDN, for Short Bowel Syndrome EducationACCESS NewswireRALEIGH, NC / ACCESSWIRE / December 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today annou
- 4y agoNMTR9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021ACCESS Newswire- Phase 2 vurolenatide VIBRANT study enrollment anticipated to be completed before year-end; topline results for short bowel syndrome expected in Q1 2022 -- Larazotide Phase 3 for celiac disease interim analysis expected in Q2 2022 -- Appointed Samantha
- 5y agoNMTR9 Meters Biopharma, Inc. Announces Immuno-Oncology Collaboration with Gustave Roussy for NM-102, a Gut Microbiome ModulatorACCESS NewswireCollaboration builds upon previous positive preclinical data warranting further investigation of NM-102, a potential novel therapy to enhance immune checkpoint inhibitor effect IND-enabling pathway for NM-102 underway with indication selection anticipa
- 5y agoNMTR9 Meters Biopharma, Inc. to Present at the 12th Annual Jefferies London Healthcare ConferenceACCESS NewswireIn-Person Dates: November 16th-17th Virtual Dates: November 18th-19th RALEIGH, NC / ACCESSWIRE / November 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating dige
- 5y agoNMTR9 Meters Biopharma, Inc. Presents Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide, Currently in Phase 2 for Short Bowel Syndrome, at the American College of Gastroenterology (ACG) 2021 Annual Scientific MeetingACCESS Newswire- Vurolenatide's half-life is consistent with twice-monthly dosing -- Top-line results from the ongoing Phase 2 VIBRANT trial on track to be reported before year's end - RALEIGH, NC / ACCESSWIRE / October 26, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR
- 5y agoNMTR9 Meters Biopharma, Inc. to Present Data on Therapeutic Candidate in Short Bowel Syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific MeetingACCESS NewswireRALEIGH, NC / ACCESSWIRE / October 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today that the com
- 5y agoNMTR9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of DirectorsACCESS NewswireRALEIGH, NC / ACCESSWIRE / October 4, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company h
- 5y agoNMTR9 Meters Biopharma, Inc. Announces Partnership with Non-Profit Gluten-Free Food Pantry Organization Mend HungerACCESS NewswireRALEIGH, NC / ACCESSWIRE / September 27, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today anno
- 5y agoNMTR9 Meters Biopharma, Inc. to Present at the Cantor Virtual Global Healthcare ConferenceACCESS Newswire- Conference Dates: September 27th-30th - RALEIGH, NC / ACCESSWIRE / September 22, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John
- 5y agoNMTR9 Meters Biopharma, Inc. to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech SummitACCESS NewswireConference Dates: September 20th-23rd RALEIGH, NC / ACCESSWIRE / September 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John Temp
- 5y agoNMTR9 Meters Biopharma, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceACCESS Newswire- Conference Dates: September 13th-15th - RALEIGH, NC / ACCESSWIRE / September 8, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John T
- 5y agoNMTR9 Meters Biopharma, Inc. to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021ACCESS Newswire- Conference Dates: September 08th-10th - RALEIGH, NC / ACCESSWIRE / September 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John T
- 5y agoNMTR9 Meters Biopharma, Inc. Announces Collaboration with EBRIS Foundation for Planned Phase 2 Study of Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C) Resulting from COVID-19ACCESS Newswire-Study May Proceed Letter Received from FDA Under Investigator IND- -EBRIS plans to initiate Phase 2a trial in MIS-C in Q4 2021 at Massachusetts General Hospital for Children- -Translational evidence reported previously in Journal of Clinical Investiga
- 5y agoNMTR9 Meters Biopharma Provides Business Update and Reports Financial Results for the Second Quarter 2021ACCESS Newswire- Initiated Phase 2 VIBRANT study of vurolenatide for short bowel syndrome (SBS) in Q2; total stool output (TSO) is primary endpoint following FDA guidance - - Expect Phase 2 data from VIBRANT in Q4 2021 - - Acquired humanized anti-GIP (glucose-depende
- 5y agoNMTR9 Meters Biopharma, Inc. to participate in BMO Capital Markets' "Biopharma Spotlight Series: Innovation in GI"ACCESS NewswireConference Call Scheduled for August 12, 2021 RALEIGH, NC / ACCESSWIRE / August 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), today announced that the Executive Management team will participate in the Biopharma Spotlight Series: Innovation in GI Co
- 5y agoNMTR9 Meters Biopharma, Inc. Announces the Acquisition of Humanized Anti-GIP Monoclonal Antibody from LobesityACCESS Newswire- Broadens existing pipeline with a monoclonal antibody against a novel target, glucose-dependent insulinotropic polypeptide (GIP) - - First planned indication is Prader-Willi Syndrome- - IND-enabling studies ongoing with first-in-human studies anticip
- 5y agoDALHPQITRMNMTR+1Thinking about buying stock in Tencent Music Entertainment, Delta Air Lines, Iterum Therapeutics, HP, or 9 Meters Biopharma?PR NewswireNEW YORK, July 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TME, DAL, ITRM, HPQ, and NMTR. To
- 5y agoDAREKSSNEGGNMTR+1Thinking about buying stock in Dare Bioscience, Newegg, Zynga, 9 Meters Biopharma, or Kohl's?PR NewswireNEW YORK, July 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DARE, NEGG, ZNGA, NMTR, and KSS. To
- 5y agoNMTR9 Meters Biopharma, Inc. To Present at the William Blair Biotech Focus ConferenceACCESS NewswireRALEIGH, NC / ACCESSWIRE / July 8, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO of 9 Meters Biopharma will participate in a virtual f
- 5y agoNMTR9 Meters Added to Russell 2000(R) and 3000(R) IndexesACCESS NewswireRALEIGH, NC / ACCESSWIRE / June 28, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today it has joined the broad-market Russell 3000® Index and the sma
- 5y agoNMTR9 Meters Announces Initiation of Phase 2 VIBRANT Study of Vurolenatide for Short Bowel SyndromeACCESS NewswireInitiating the largest Phase 2 placebo-controlled trial in short bowel syndrome Topline results of the multicenter VIBRANT study anticipated in Q4 2021 RALEIGH, NC / ACCESSWIRE / June 14, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage